Cargando…
Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib
With the rapid development and adoption of novel anti-cancer therapeutics, physicians commonly encounter cancer patients on regimens with recently approved drugs for which information about rare or long-term side effects may not be available. In this case, we present a young woman with cholangiocarc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255035/ https://www.ncbi.nlm.nih.gov/pubmed/34258110 http://dx.doi.org/10.7759/cureus.15441 |
_version_ | 1783717826726461440 |
---|---|
author | Papaila, Alexa Jacobson, Alexis T |
author_facet | Papaila, Alexa Jacobson, Alexis T |
author_sort | Papaila, Alexa |
collection | PubMed |
description | With the rapid development and adoption of novel anti-cancer therapeutics, physicians commonly encounter cancer patients on regimens with recently approved drugs for which information about rare or long-term side effects may not be available. In this case, we present a young woman with cholangiocarcinoma who was treated with the rearranged during transfection (RET)-selective tyrosine kinase inhibitor (TKI), pralsetinib, and presented to the hospital with shortness of breath. We review her diagnosis of new-onset systolic dysfunction as a possible sequela of her TKI therapy to encourage ongoing efforts to enhance provider familiarity with the side effects of this important and increasingly prescribed drug class. |
format | Online Article Text |
id | pubmed-8255035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-82550352021-07-12 Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib Papaila, Alexa Jacobson, Alexis T Cureus Cardiology With the rapid development and adoption of novel anti-cancer therapeutics, physicians commonly encounter cancer patients on regimens with recently approved drugs for which information about rare or long-term side effects may not be available. In this case, we present a young woman with cholangiocarcinoma who was treated with the rearranged during transfection (RET)-selective tyrosine kinase inhibitor (TKI), pralsetinib, and presented to the hospital with shortness of breath. We review her diagnosis of new-onset systolic dysfunction as a possible sequela of her TKI therapy to encourage ongoing efforts to enhance provider familiarity with the side effects of this important and increasingly prescribed drug class. Cureus 2021-06-04 /pmc/articles/PMC8255035/ /pubmed/34258110 http://dx.doi.org/10.7759/cureus.15441 Text en Copyright © 2021, Papaila et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Papaila, Alexa Jacobson, Alexis T Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title | Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title_full | Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title_fullStr | Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title_full_unstemmed | Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title_short | Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib |
title_sort | into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255035/ https://www.ncbi.nlm.nih.gov/pubmed/34258110 http://dx.doi.org/10.7759/cureus.15441 |
work_keys_str_mv | AT papailaalexa intotheunknownacaseofnewonsetcardiomyopathyinapatienttreatedwithrecentlyapprovedtyrosinekinaseinhibitorpralsetinib AT jacobsonalexist intotheunknownacaseofnewonsetcardiomyopathyinapatienttreatedwithrecentlyapprovedtyrosinekinaseinhibitorpralsetinib |